Mylan Fights FDA On Teva's Provigil Market Rights

Law360, Washington (April 18, 2012, 6:14 PM EDT) -- Mylan Inc. asked a federal judge Wednesday to block the U.S. Food and Drug Administration's decision giving Teva Pharmaceuticals USA Inc. 180-day exclusivity to market a generic version of Provigil, arguing Teva and its affiliate Cephalon Inc. had worked together to stymie generic competition of the Cephalon sleep disorder drug.

Mylan is requesting a preliminary injunction in the case to halt an FDA decision giving Teva exclusive rights to market a generic version of Provigil, or modafinil, despite Mylan's 2002 abbreviated new drug application for a...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

MYLAN PHARMACEUTICALS INC. v. SEBELIUS et al


Case Number

1:12-cv-00524

Court

District Of Columbia

Nature of Suit

Other Statutory Actions

Judge

Ellen S. Huvelle

Date Filed

April 4, 2012

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.